International Trends in Decision-making Regarding Risk-reducing Salpingo-oophorectomy for Hereditary Breast and Ovarian Cancer Syndrome
-
- Imai Yoshie
- Tokushima University, Tokushima, Japan
-
- Mori Yuka
- Tokushima University, Tokushima, Japan
-
- Mitarai Sachiko
- NTT Medical Center Tokyo, Tokyo, Japan
-
- Irisawa Yuko
- The University of Tokyo Hospital, Tokyo, Japan
-
- Ookawa Megumi
- St Luke’s International Hospital, Tokyo, Japan
-
- Hinoshita Saki
- Hyogo Cancer Center, Hyogo, Japan
-
- Shimokawa Aya
- National Hospital Organization Kokura Medical Center, Fukuoka, Japan
-
- Notomi Rie
- Akita University Hospital, Akita, Japan
-
- Matsumoto Hitomi
- Hyogo Prefectual Harima-Himeji General Medical Center, Hyogo, Japan
-
- Abe Akiko
- Cancer Institute Hospital, Tokyo, Japan
-
- Yoshida Kanako
- Tokushima University, Tokushima, Japan
-
- Murakami Yoshie
- Toho University, Tokyo, Japan
-
- Takeda Yuko
- Keio University, Tokyo, Japan
-
- Kawasaki Yuko
- University of Hyogo, Hyogo, Japan
-
- Sakamoto Tomoka
- Tokushima University, Tokushima, Japan
Bibliographic Information
- Other Title
-
- 遺伝性乳がん卵巣がん症候群に対するリスク低減卵巣卵管摘出術への意思決定に関する海外の動向
Search this article
Description
<p>Hereditary breast and ovarian cancer syndrome (HBOC) has been reported to account for about 10-15% of all ovarian cancers, and risk-reducing salpingo-oophorectomy (RRSO) is regarded as the only preventive measure against the risk of such cancers. It is important for patients with BRCA 1/2 pathogenic variants to undergo RRSO after childbearing, between the ages of 35 to 45, but a multifaceted perspective is needed when considering this procedure, as it may cause physical and psychological problems. This paper discusses factors that influence decision-making regarding RRSO from three perspectives : demographics, medical history, and psychosociology, with reference to previous studies. Accurate insight into the background that led to the decision to undergo RRSO is crucial for support. Above all, it is essential to utilize such insight in healthcare as vital information to prevent death from breast or ovarian cancer among HBOC patients.</p>
Journal
-
- SHIKOKU ACTA MEDICA
-
SHIKOKU ACTA MEDICA 79 (5.6), 245-252, 2024
Tokushima Medical Association
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390862566410144512
-
- ISSN
- 27583279
- 00373699
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed